Robotic Partial Nephrectomy with En Bloc Removal of a Renal Vein Thrombus for Multiple cT3a Renal Cell Carcinoma Lesions.

Cognitive surgery Partial nephrectomy Renal cell carcinoma Robotic Three-dimensional models

Journal

European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568

Informations de publication

Date de publication:
Oct 2022
Historique:
accepted: 04 08 2022
entrez: 1 9 2022
pubmed: 2 9 2022
medline: 2 9 2022
Statut: epublish

Résumé

Partial nephrectomy (PN) may be recommended for selected patients with advanced-stage (>cT2) renal cell carcinoma (RCC) with the aim of avoiding dialysis and chronic kidney disease-related comorbidities. The spread of robotic surgery has led to expansion of PN indications to more challenging scenarios and even frontier surgeries, including advanced-stage RCC. Here we describe the management of a patient with a solitary kidney diagnosed with multiple cT3a (renal vein thrombus) RCC who was treated using a conservative robotic approach. The most crucial surgical considerations for this procedure were: (1) tailored planning of the surgical approach using three-dimensional reconstruction software; (2) accurate boundary delineation for the tumors and thrombus; (3) avoiding unnecessary warm ischemia time; (4) performing an anatomical excision to follow eventual tumor bulging; and (5) en bloc removal of the main lesion and its thrombus. No perioperative complications were recorded. Histopathology revealed clear cell RCC for all four lesions with nucleolar grade 3 and negative surgical margins. At 12-mo follow-up the patient was disease-free. When performed by an experienced surgeon, PN plus venous thrombus excision for imperative cases with cT3 RCC may represent a valid treatment option with valuable oncological and functional outcomes. We describe the case of patient who had a single kidney with multiple kidney tumors and tumor extension into a blood vessel. The patient was treated with robot-assisted removal of the tumors, sparing as much kidney tissue as possible. This technique was found to be safe and effective, with no complications and good intermediate-term results.

Identifiants

pubmed: 36046617
doi: 10.1016/j.euros.2022.08.002
pii: S2666-1683(22)00861-8
pmc: PMC9421307
doi:

Types de publication

Journal Article

Langues

eng

Pagination

33-36

Informations de copyright

© 2022 The Authors.

Références

Int Braz J Urol. 2021 Nov-Dec;47(6):1272-1273
pubmed: 34156192
Eur Urol Open Sci. 2021 Sep 27;33:42-44
pubmed: 34632421
Minerva Urol Nephrol. 2021 Aug;73(4):540-543
pubmed: 33200907
Eur J Surg Oncol. 2022 Mar;48(3):687-693
pubmed: 34862095
Urol Oncol. 2018 Jul;36(7):339.e1-339.e8
pubmed: 29801993
Minerva Urol Nephrol. 2022 Apr;74(2):186-193
pubmed: 35345387

Auteurs

Antonio Andrea Grosso (AA)

Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Diego Marcos Marìn (DM)

Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

Fabrizio Di Maida (F)

Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Maria Lucia Gallo (ML)

Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Luca Lambertini (L)

Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Samuele Nardoni (S)

Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Andrea Mari (A)

Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Andrea Minervini (A)

Department of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.

Classifications MeSH